Logo image of ATHE

ALTERITY THERAPEUTICS-ADR (ATHE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ATHE - US02155X2053 - ADR

3.13 USD
+0.04 (+1.29%)
Last: 12/22/2025, 12:24:05 PM
Fundamental Rating

4

Overall ATHE gets a fundamental rating of 4 out of 10. We evaluated ATHE against 530 industry peers in the Biotechnology industry. The financial health of ATHE is average, but there are quite some concerns on its profitability. ATHE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ATHE had negative earnings in the past year.
ATHE had a negative operating cash flow in the past year.
In the past 5 years ATHE always reported negative net income.
ATHE had a negative operating cash flow in each of the past 5 years.
ATHE Yearly Net Income VS EBIT VS OCF VS FCFATHE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M

1.2 Ratios

With a decent Return On Assets value of -26.39%, ATHE is doing good in the industry, outperforming 70.19% of the companies in the same industry.
ATHE's Return On Equity of -28.65% is fine compared to the rest of the industry. ATHE outperforms 77.36% of its industry peers.
Industry RankSector Rank
ROA -26.39%
ROE -28.65%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATHE Yearly ROA, ROE, ROICATHE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATHE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATHE Yearly Profit, Operating, Gross MarginsATHE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200K -400K -600K

More info and screens

6

2. Health

2.1 Basic Checks

ATHE does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ATHE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ATHE Yearly Shares OutstandingATHE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
ATHE Yearly Total Debt VS Total AssetsATHE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 7.43 indicates that ATHE is not in any danger for bankruptcy at the moment.
ATHE has a better Altman-Z score (7.43) than 78.11% of its industry peers.
ATHE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ATHE has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.43
ROIC/WACCN/A
WACC9.06%
ATHE Yearly LT Debt VS Equity VS FCFATHE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M 30M

2.3 Liquidity

A Current Ratio of 12.98 indicates that ATHE has no problem at all paying its short term obligations.
ATHE has a better Current ratio (12.98) than 88.30% of its industry peers.
A Quick Ratio of 12.98 indicates that ATHE has no problem at all paying its short term obligations.
ATHE's Quick ratio of 12.98 is amongst the best of the industry. ATHE outperforms 88.30% of its industry peers.
Industry RankSector Rank
Current Ratio 12.98
Quick Ratio 12.98
ATHE Yearly Current Assets VS Current LiabilitesATHE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

8

3. Growth

3.1 Past

ATHE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.62%, which is quite impressive.
The Revenue has grown by 66.28% in the past year. This is a very strong growth!
Measured over the past years, ATHE shows a very strong growth in Revenue. The Revenue has been growing by 92.01% on average per year.
EPS 1Y (TTM)59.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.08%
Revenue 1Y (TTM)66.28%
Revenue growth 3Y463.07%
Revenue growth 5Y92.01%
Sales Q2Q%123.33%

3.2 Future

ATHE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.99% yearly.
ATHE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 225.71% yearly.
EPS Next Y100%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year1289.71%
Revenue Next 2Y261.09%
Revenue Next 3Y411.28%
Revenue Next 5Y225.71%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ATHE Yearly Revenue VS EstimatesATHE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2030 2031 2032 200M 400M 600M 800M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ATHE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATHE Price Earnings VS Forward Price EarningsATHE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATHE Per share dataATHE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ATHE's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATHE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ALTERITY THERAPEUTICS-ADR

NASDAQ:ATHE (12/22/2025, 12:24:05 PM)

3.13

+0.04 (+1.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-29 2025-08-29
Earnings (Next)02-26 2026-02-26
Inst Owners18.19%
Inst Owner Change50.83%
Ins Owners2.97%
Ins Owner ChangeN/A
Market Cap56.73M
Revenue(TTM)446.30K
Net Income(TTM)-12.15M
Analysts100
Price TargetN/A
Short Float %0.14%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 192.54
P/FCF N/A
P/OCF N/A
P/B 2.03
P/tB 2.03
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.02
BVpS1.54
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.39%
ROE -28.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.98
Quick Ratio 12.98
Altman-Z 7.43
F-Score5
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)15.55%
Cap/Sales(5y)732.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.08%
EPS Next Y100%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)66.28%
Revenue growth 3Y463.07%
Revenue growth 5Y92.01%
Sales Q2Q%123.33%
Revenue Next Year1289.71%
Revenue Next 2Y261.09%
Revenue Next 3Y411.28%
Revenue Next 5Y225.71%
EBIT growth 1Y26.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-118.69%
EBIT Next 3Y118.15%
EBIT Next 5YN/A
FCF growth 1Y9.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.16%
OCF growth 3YN/A
OCF growth 5YN/A

ALTERITY THERAPEUTICS-ADR / ATHE FAQ

What is the fundamental rating for ATHE stock?

ChartMill assigns a fundamental rating of 4 / 10 to ATHE.


What is the valuation status for ATHE stock?

ChartMill assigns a valuation rating of 1 / 10 to ALTERITY THERAPEUTICS-ADR (ATHE). This can be considered as Overvalued.


What is the profitability of ATHE stock?

ALTERITY THERAPEUTICS-ADR (ATHE) has a profitability rating of 1 / 10.


How financially healthy is ALTERITY THERAPEUTICS-ADR?

The financial health rating of ALTERITY THERAPEUTICS-ADR (ATHE) is 6 / 10.